ELAN.N
Latest Trade
26.67USDChange
0.32(+1.21%)Volume
372,225Today's Range
-
27.0052 Week Range
-
35.46As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 26.35 |
|---|---|
Open | 26.73 |
Volume | 372,225 |
3M AVG Volume | 86.25 |
Today's High | 27.00 |
Today's Low | 26.39 |
52 Week High | 35.46 |
52 Week Low | 25.25 |
Shares Out (MIL) | 373.00 |
Market Cap (MIL) | 9,828.66 |
Forward P/E | 24.72 |
Dividend (Yield %) | -- |
Elanco Animal Health Q3 Adjusted Earnings Per Share $0.30 Including Items
Elanco Intends To Eliminate Approximately 250 Positions Across Multiple Locations And Functions
Elanco Animal Health CEO Jeffrey N Simmons Reports Open Market Purchase Of 75,750 Shares At Average Price Of $26.55 On Sept 4
Elanco Animal Health Incorporated is an animal health company that develops, manufactures and markets products for companion and food animals. The Company offers its products under four primary categories, such as Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. It provides a range of parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. It also offers a pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. It also provides treatments for otitis (ear infections), as well as cardiovascular and dermatology indications. Its portfolio in Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics. It also provides products in poultry and aquaculture production.
Industry
Biotechnology & Drugs
Executive Leadership
R. David Hoover
Independent Chairman of the Board
Jeffrey N. Simmons
President, Chief Executive Officer, Director
Todd S. Young
Chief Financial Officer, Executive Vice President
Michael-Bryant Hicks
Executive Vice President, General Counsel, Corporate Secretary
David S. Kinard
Executive Vice President of Human Resources
Price To Earnings (TTM) | 103.12 |
|---|---|
Price To Sales (TTM) | 3.19 |
Price To Book (MRQ) | 1.79 |
Price To Cash Flow (TTM) | 24.66 |
Total Debt To Equity (MRQ) | 43.01 |
LT Debt To Equity (MRQ) | 42.56 |
Return on Investment (TTM) | 1.17 |
Return on Equity (TTM) | 1.04 |
Elanco Animal Health <ELAN.N> agreed to buy Bayer's <BAYGn.DE> veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion, creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.
Elanco Animal Health Inc said on Tuesday it would buy Bayer AG's animal health unit in a cash and stock deal valued at $7.6 billion, a move that would create the second largest animal health business and expand Elanco's reach in the pet e-commerce space.
Germany's Bayer AG and U.S. drug firm Elanco Animal Health Inc aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported https://www.bloomberg.com/news/articles/2019-08-07/elanco-bayer-said-aiming-to-reach-animal-health-deal-next-week...
Germany's Bayer AG <BAYGn.DE> and U.S. drug firm Elanco Animal Health Inc <ELAN.N> aim to reach an agreement to combine their pet-health businesses as soon as next week, Bloomberg reported on Wednesday, citing people with knowledge of the matter.
Bayer <BAYGn.DE> has approached U.S. drug firm Elanco Animal Health <ELAN.N> to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.